PerkinElmer-ViaCell Deal Clears Antitrust Hurdle


Yesterday marked the expiration of the antitrust waiting period for Waltham, MA-based PerkinElmer’s (NYSE: PKI) planned acquisition of Cambridge’s ViaCell (NASDAQ: VIAC). The $300 million deal, announced about three weeks ago, boosted ViaCell’s shares more than 50 percent, and should close later this quarter.

By posting a comment, you agree to our terms and conditions.